Researchers say this is the first combination therapy that targets two different cancer survival mechanism: PARP and WNT signaling.
News-Medical.Net on MSN
New drug combination shows promise for overcoming resistance in ovarian cancer
Researchers at the University of Colorado Cancer Center have discovered a novel therapy combination that could offer new hope ...
Researchers at the University of Colorado Cancer Center have discovered a novel therapy combination that could offer new hope ...
Laigo Bio’s SureTAC™ membrane protein degradation technology targets key signaling molecules in autoimmune, graft rejection, and oncology UTRECHT, the Netherlands - 4 December 2025 (08:30 CET). Laigo ...
A study led by researchers at the Hospital del Mar Research Institute advances one of the most significant milestones in ...
News Medical on MSN
Pathway discovered to make the most common breast cancer tumor responsive to immunotherapy
A study from the Hospital del Mar Research Institute, published in The Journal of Clinical Investigation, indicates that the high expression of the estrogen receptor is the main factor preventing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback